metabolomic analysis are great enough to be significantly higher than the biological variability among a population.

Although metabolomics can make a valuable contribution to understanding disease, researchers continue to characterize disease from the perspective of different disciplines (e.g., pathology, physiology, and clinical chemistry). Weinberger asserted that the community must aim to unite these different disciplines in the assessment of molecular pathology. Further, he suggested that throughout the pharmaceutical industry, pharmacology, preclinical, clinical, and toxicology departments should focus on the same question of drug reaction utilizing all available perspectives. Such unification of disciplines could help reinforce evidence-based drug development.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement